Peter Isakson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Anatomy

B-Lymphocytes

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gierse James K; Zhang Yan; Hood William F; Walker Mark C; Trigg Jennifer S; Maziasz Timothy J; Koboldt Carol M; Muhammad Jerry L; Zweifel Ben S; Masferrer Jaime L; Isakson Peter C; Seibert Karen
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
Gyllfors Pär; Bochenek Grazyna; Overholt John; Drupka Diane; Kumlin Maria; Sheller James; Nizankowska Ewa; Isakson Peter C; Mejza Filip; Lefkowith James B; Dahlén Sven-Erik; Szczeklik Andrew; Murray John J; Dahlén Barbro
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
Hood William F; Gierse James K; Isakson Peter C; Kiefer James R; Kurumbail Ravi G; Seibert Karen; Monahan Joseph B
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Isakson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2005: Gierse James K; Zhang Yan; Hood William F; Walker Mark C; Trigg Jennifer S; Maziasz Timothy J; Koboldt Carol M; Muhammad Jerry L; Zweifel Ben S; Masferrer Jaime L; Isakson Peter C; Seibert Karen
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1206-12.
2003: Gyllfors Pär; Bochenek Grazyna; Overholt John; Drupka Diane; Kumlin Maria; Sheller James; Nizankowska Ewa; Isakson Peter C; Mejza Filip; Lefkowith James B; Dahlén Sven-Erik; Szczeklik Andrew; Murray John J; Dahlén Barbro
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
The Journal of allergy and clinical immunology 2003;111(5):1116-21.
2003: Hood William F; Gierse James K; Isakson Peter C; Kiefer James R; Kurumbail Ravi G; Seibert Karen; Monahan Joseph B
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
Molecular pharmacology 2003;63(4):870-7.
2003: Isakson Peter C
Pharmacology of COX-2 inhibitors.
Progress in experimental tumor research. Fortschritte der experimentellen Tumorforschung. Progrès de la recherche expérimentale des tumeurs 2003;37():25-51.
2003: Vidensky Svetlana; Zhang Yan; hand Tracey; Goellner Joe; Shaffer Alex; Isakson Peter; Andreasson Katrin
Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response.
Neuromolecular medicine 2003;3(1):15-28.
2002: Ciceri Paola; Zhang Yan; Shaffer Alex F; Leahy Kathleen M; Woerner Mark B; Smith Walter G; Seibert Karen; Isakson Peter C
Pharmacology of celecoxib in rat brain after kainate administration.
The Journal of pharmacology and experimental therapeutics 2002;302(3):846-52.
2002: Gierse James; Kurumbail Ravi; Walker Mark; Hood Bill; Monahan Joe; Pawlitz Jennifer; Stegeman Rick; Stevens Anna; Kiefer Jim; Koboldt Carol; Moreland Kirby; Rowlinson Scott; Marnett Larry; Pierce Jennifer; Carter Jeff; Talley John; Isakson Peter; Seibert Karen
Mechanism of inhibition of novel COX-2 inhibitors.
Advances in experimental medicine and biology 2002;507():365-9.
2002: Koki Alane; Khan Nasir K; Woerner B Mark; Dannenberg A J; Olson Lisa; Seibert Karen; Edwards Dorothy; Hardy Madorra; Isakson Peter; Masferrer Jaime L
Cyclooxygenase-2 in human pathological disease.
Advances in experimental medicine and biology 2002;507():177-84.
2001: Andreasson K I; Savonenko A; Vidensky S; Goellner J J; Zhang Y; Shaffer A; Kaufmann W E; Worley P F; Isakson P; Markowska A L
Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(20):8198-209.
2001: Walker M C; Kurumbail R G; Kiefer J R; Moreland K T; Koboldt C M; Isakson P C; Seibert K; Gierse J K
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
The Biochemical journal 2001;357(Pt 3):709-18.
2001: Verburg K M; Maziasz T J; Weiner E; Loose L; Geis G S; Isakson P C
Cox-2-specific inhibitors: definition of a new therapeutic concept.
American journal of therapeutics 2001;8(1):49-64.
2000: Khanna I K; Yu Y; Huff R M; Weier R M; Xu X; Koszyk F J; Collins P W; Cogburn J N; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Veenhuizen A W; Yuan J; Yang D C; Zhang Y Y
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Journal of medicinal chemistry 2000;43(16):3168-85.
2000: Whelton A; Schulman G; Wallemark C; Drower E J; Isakson P C; Verburg K M; Geis G S
Effects of celecoxib and naproxen on renal function in the elderly.
Archives of internal medicine 2000;160(10):1465-70.
2000: Leese P T; Hubbard R C; Karim A; Isakson P C; Yu S S; Geis G S
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
Journal of clinical pharmacology 2000;40(2):124-32.
1999: Emery P; Zeidler H; Kvien T K; Guslandi M; Naudin R; Stead H; Verburg K M; Isakson P C; Hubbard R C; Geis G S
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
Lancet 1999;354(9196):2106-11.
1999: Simon L S; Weaver A L; Graham D Y; Kivitz A J; Lipsky P E; Hubbard R C; Isakson P C; Verburg K M; Yu S S; Zhao W W; Geis G S
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;282(20):1921-8.
1999: Bensen W G; Fiechtner J J; McMillen J I; Zhao W W; Yu S S; Woods E M; Hubbard R C; Isakson P C; Verburg K M; Geis G S
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Mayo Clinic proceedings. Mayo Clinic 1999;74(11):1095-105.
1999: Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
COX-2 inhibitors--is there cause for concern?
Nature medicine 1999;5(6):621-2.
1999: Gierse J K; Koboldt C M; Walker M C; Seibert K; Isakson P C
Kinetic basis for selective inhibition of cyclo-oxygenases.
The Biochemical journal 1999;339 ( Pt 3)():607-14.
1999: Margalit A; Hauser S D; Isakson P C
Regulation of in vivo prostaglandin biosynthesis by glutathione.
Advances in experimental medicine and biology 1999;469():165-8.
1998: Smith C J; Zhang Y; Koboldt C M; Muhammad J; Zweifel B S; Shaffer A; Talley J J; Masferrer J L; Seibert K; Isakson P C
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(22):13313-8.
1998: Simon L S; Lanza F L; Lipsky P E; Hubbard R C; Talwalker S; Schwartz B D; Isakson P C; Geis G S
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Arthritis and rheumatism 1998;41(9):1591-602.
1998: Margalit A; Hauser S D; Zweifel B S; Anderson M A; Isakson P C
Regulation of prostaglandin biosynthesis in vivo by glutathione.
The American journal of physiology 1998;274(2 Pt 2):R294-302.
1998: Venturini C M; Isakson P; Needleman P
Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms.
Current opinion in nephrology and hypertension 1998;7(1):79-82.
1997: Zhang Y; Shaffer A; Portanova J; Seibert K; Isakson P C
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1069-75.
1997: Kaufmann W E; Andreasson K I; Isakson P C; Worley P F
Cyclooxygenases and the central nervous system.
Prostaglandins 1997;54(3):601-24.
1997: Needleman P; Isakson P C
The discovery and function of COX-2.
The Journal of rheumatology. Supplement 1997;49():6-8.
1997: Khanna I K; Weier R M; Yu Y; Xu X D; Koszyk F J; Collins P W; Koboldt C M; Veenhuizen A W; Perkins W E; Casler J J; Masferrer J L; Zhang Y Y; Gregory S A; Seibert K; Isakson P C
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
Journal of medicinal chemistry 1997;40(11):1634-47.
1997: Khanna I K; Weier R M; Yu Y; Collins P W; Miyashiro J M; Koboldt C M; Veenhuizen A W; Currie J L; Seibert K; Isakson P C
1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2.
Journal of medicinal chemistry 1997;40(11):1619-33.
1997: Margalit A; Duffin K L; Shaffer A F; Gregory S A; Isakson P C
Altered arachidonic acid metabolism in urate crystal induced inflammation.
Inflammation 1997;21(2):205-22.
1997: Penning T D; Talley J J; Bertenshaw S R; Carter J S; Collins P W; Docter S; Graneto M J; Lee L F; Malecha J W; Miyashiro J M; Rogers R S; Rogier D J; Yu S S; AndersonGD; Burton E G; Cogburn J N; Gregory S A; Koboldt C M; Perkins W E; Seibert K; Veenhuizen A W; Zhang Y Y; Isakson P C
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Journal of medicinal chemistry 1997;40(9):1347-65.
1997: Kaufmann W E; Worley P F; Taylor C V; Bremer M; Isakson P C
Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome.
Brain & development 1997;19(1):25-34.
1997: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Isakson P
Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Advances in experimental medicine and biology 1997;400A():167-70.
1996: Weber J D; Isakson P C; Purkerson J M
IL-5 receptor expression and Ig secretion from murine B lymphocytes requires coordinated signaling by membrane Ig, IL-4, and IL-5.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(10):4428-35.
1996: Portanova J P; Zhang Y; Anderson G D; Hauser S D; Masferrer J L; Seibert K; Gregory S A; Isakson P C
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.
The Journal of experimental medicine 1996;184(3):883-91.
1996: Anderson G D; Hauser S D; McGarity K L; Bremer M E; Isakson P C; Gregory S A
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
The Journal of clinical investigation 1996;97(11):2672-9.
1996: Li J J; Norton M B; Reinhard E J; Anderson G D; Gregory S A; Isakson P C; Koboldt C M; Masferrer J L; Perkins W E; Seibert K; Zhang Y; Zweifel B S; Reitz D B
Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1996;39(9):1846-56.
1996: Margalit A; Duffin K L; Isakson P C
Rapid quantitation of a large scope of eicosanoids in two models of inflammation: development of an electrospray and tandem mass spectrometry method and application to biological studies.
Analytical biochemistry 1996;235(1):73-81.
1996: Kaufmann W E; Worley P F; Pegg J; Bremer M; Isakson P
COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2317-21.
1996: Huang H C; Li J J; Garland D J; Chamberlain T S; Reinhard E J; Manning R E; Seibert K; Koboldt C M; Gregory S A; Anderson G D; Veenhuizen A W; Zhang Y; Perkins W E; Burton E G; Cogburn J N; Isakson P C; Reitz D B
Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationships.
Journal of medicinal chemistry 1996;39(1):253-66.
1995: Smith W G; Shaffer A F; Currie J L; Thompson J M; Kim S; Rao T; Isakson P C
Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
The Journal of pharmacology and experimental therapeutics 1995;275(3):1332-8.
1995: Mnich S J; Veenhuizen A W; Monahan J B; Sheehan K C; Lynch K R; Isakson P C; Portanova J P
Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(9):4437-44.
1995: Li J J; Anderson G D; Burton E G; Cogburn J N; Collins J T; Garland D J; Gregory S A; Huang H C; Isakson P C; Koboldt C M
1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.
Journal of medicinal chemistry 1995;38(22):4570-8.
1995: Huff R; Collins P; Kramer S; Seibert K; Koboldt C; Gregory S; Isakson P
A structural feature of N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398) that governs its selectivity and affinity for cyclooxygenase 2 (COX2).
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1995;44 Suppl 2():S145-6.
1995: Fretland D J; Anglin C P; Bremer M; Isakson P; Widomski D L; Paulson S K; Docter S H; Djuric S W; Penning T D; Yu S
Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.
Inflammation 1995;19(2):193-205.
1995: Gierse J K; Hauser S D; Creely D P; Koboldt C; Rangwala S H; Isakson P C; Seibert K
Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.
The Biochemical journal 1995;305 ( Pt 2)():479-84.
1995: Isakson P; Seibert K; Masferrer J; Salvemini D; Lee L; Needleman P
Discovery of a better aspirin.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():49-54.
1995: Welsch D J; Creely D P; Mathis K J; Hauser S D; Isakson P C
Molecular cloning and expression of human leukotriene C4 synthase.
Advances in prostaglandin, thromboxane, and leukotriene research 1995;23():167-9.
1995: Seibert K; Masferrer J; Zhang Y; Gregory S; Olson G; Hauser S; Leahy K; Perkins W; Isakson P
Mediation of inflammation by cyclooxygenase-2.
Agents and actions. Supplements 1995;46():41-50.
1994: Seibert K; Zhang Y; Leahy K; Hauser S; Masferrer J; Perkins W; Lee L; Isakson P
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12013-7.
1994: Isakson P; Hauser S; Zhang Y; Leahy K; Masferrer J; Seibert K
Cytokine regulation of eicosanoid generation.
Annals of the New York Academy of Sciences 1994;744():181-3.
1994: Welsch D J; Creely D P; Hauser S D; Mathis K J; Krivi G G; Isakson P C
Molecular cloning and expression of human leukotriene-C4 synthase.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(21):9745-9.
1994: Rao T S; Yu S S; Djuric S W; Isakson P C
Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
Journal of lipid mediators and cell signalling 1994;10(3):213-28.
1994: Purkerson J M; Isakson P C
Independent regulation of DNA recombination and immunoglobulin (Ig) secretion during isotype switching to IgG1 and IgE.
The Journal of experimental medicine 1994;179(6):1877-83.
1994: Rao T S; Currie J L; Shaffer A F; Isakson P C
In vivo characterization of zymosan-induced mouse peritoneal inflammation.
The Journal of pharmacology and experimental therapeutics 1994;269(3):917-25.
1994: Masferrer J L; Zweifel B S; Manning P T; Hauser S D; Leahy K M; Smith W G; Isakson P C; Seibert K
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(8):3228-32.
1994: Rao T S; Shaffer A F; Currie J L; Isakson P C
Role of mast cells in calcium ionophore (A23187)-induced peritoneal inflammation in mice.
Inflammation 1994;18(2):187-92.
1993: Rao T S; Currie J L; Shaffer A F; Isakson P C
Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation.
Inflammation 1993;17(6):723-41.
1993: Rao T S; Currie J L; Shaffer A F; Isakson P C
Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
Life sciences 1993;53(9):PL147-52.
1992: Purkerson J; Isakson P
A two-signal model for regulation of immunoglobulin isotype switching.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1992;6(14):3245-52.
1992: Purkerson J M; Isakson P C
Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE.
The Journal of experimental medicine 1992;175(4):973-82.
1992: Catron K M; Purkerson J M; Isakson P C; Bender T P
Constitutive versus cell cycle regulation of c-myb mRNA expression correlates with developmental stages in murine B lymphoid tumors.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(3):934-42.
1991: Isakson P C; Purkerson J; Catron K; Bender T P
A novel method for synchronizing a B cell lymphoma.
Journal of immunological methods 1991;145(1-2):137-42.
1991: Purkerson J M; Isakson P C
Isotype switching in anti-immunoglobulin-activated B lymphoblasts: differential requirements for interleukin 4 and other lymphokines to elicit membrane vs. secreted IgG1.
European journal of immunology 1991;21(3):707-14.
1990: Catron K M; Toth C R; Purkerson J; Isakson P; Bender T P
Constitutive and cell cycle regulated expression of c-myc mRNA is related to the state of differentiation in murine B-lymphoid tumors.
Current topics in microbiology and immunology 1990;166():197-202.
1989: Isakson P C; D'Angelo D; Schetz J; Tardelli L; Puré E
Anti-Ig-stimulated B lymphoblasts can be restimulated via their surface Ig.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(12):3901-8.
1989: Simpson L; McNiece I; Newberg M; Schetz J; Lynch K R; Quesenberry P; Isakson P C
Detection and characterization of a B cell stimulatory factor (BSF-TC) derived from a bone marrow stromal cell line.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(11):3894-900.
1988: Purkerson J M; Newberg M; Wise G; Lynch K R; Isakson P C
Interleukin 5 and interleukin 2 cooperate with interleukin 4 to induce IgG1 secretion from anti-Ig-treated B cells.
The Journal of experimental medicine 1988;168(3):1175-80.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Peter Isakson

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Peter Isakson (preview)

All Publications